Bausch & Lomb (BLCO) Cash from Financing Activities (2021 - 2026)
Bausch & Lomb (BLCO) reported Cash from Financing Activities of -$20.0 million for Q1 2026, down 164.52% on a YoY basis from $31.0 million in Q1 2025, and down 117.24% quarter-over-quarter from $116.0 million in Q4 2025.
Bausch & Lomb (BLCO) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Bausch & Lomb has reported Cash from Financing Activities for 6 years, with the latest figure at -$20.0 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 164.52% year-over-year to -$20.0 million; the trailing twelve-month figure through Mar 2026 stood at $174.0 million (down 11.68% YoY), and the FY2025 full-year result was $225.0 million, up 26.4% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$20.0 million, down from $116.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $1.8 billion in Q3 2023, with the low at -$109.0 million in Q3 2022.
- Historically, Cash from Financing Activities has averaged $149.5 million across 5 years, with a median of $52.0 million in 2022.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 1761.47% — and 2026, when it slumped 164.52%.
- Bausch & Lomb's Cash from Financing Activities stood at -$7.0 million in 2022, then soared by 1328.57% to $86.0 million in 2023, then soared by 69.77% to $146.0 million in 2024, then fell by 20.55% to $116.0 million in 2025, then plunged by 117.24% to -$20.0 million in 2026.
- The last three Cash from Financing Activities figures came in at -$20.0 million (Q1 2026), $116.0 million (Q4 2025), and -$12.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | -1.35 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -414.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | -13.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | -255.24 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | -308.70 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | -50.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -75.80 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | -48.13 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -11.00 Mn |
| 10 | Bausch & Lomb | 5.32 Bn | 5.12 Bn | 973.00 Mn | -20.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.00 Mn |
| Mar 31, 2026 | -20.00 Mn |
| Dec 31, 2025 | 116.00 Mn |
| Dec 31, 2025 | 116.00 Mn |
| Sep 30, 2025 | -12.00 Mn |
| Sep 30, 2025 | -12.00 Mn |
| Jun 30, 2025 | 90.00 Mn |
| Jun 30, 2025 | 90.00 Mn |
| Mar 31, 2025 | 31.00 Mn |
| Mar 31, 2025 | 31.00 Mn |
| Dec 31, 2024 | 146.00 Mn |
| Dec 31, 2024 | 146.00 Mn |
| Sep 30, 2024 | -20.00 Mn |
| Sep 30, 2024 | -20.00 Mn |
| Jun 30, 2024 | 40.00 Mn |
| Jun 30, 2024 | 40.00 Mn |
| Mar 31, 2024 | 12.00 Mn |
| Mar 31, 2024 | 12.00 Mn |
| Dec 31, 2023 | 86.00 Mn |
| Dec 31, 2023 | 86.00 Mn |